WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

Koninklijke Philips N.V. PHIA

AmsterdamMedical devicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
PHIA financials
Moat score
77
ROIC
8.0%
P/E
27.7
EV/EBIT
19.8
FCF yield
6.9%
Dividend yield
1.4%
Market cap
€26.5B

Moat ranks

Score rankTied #182 of 396
Durabilitydurable
Market structureOligopoly
Pricing powermoderate

Balance sheet

12/31/25
€BDec '24Dec '25
Cash2.42.8
Securities0.00.0
Debt6.67.1
Net cash-4.2-4.3
Equity12.011.0
Leverage
Debt / EBITDA
2.60×
Debt / equity
0.65×
Leases (6/30/26)
€953M
Capital
Diluted shares
990M
Book value / share
€11.07
Price / book
2.4×
Net cash / share
−€4.37
Market cap
€26.5B
Enterprise value
€30.8B

Per-share record

Fiscal years and TTM
Scale
−€5€0€5€10€15€20'16'17'18'19'20'21'22'23'2418.53'2517.94TTM
Revenue per shareCash flow per share

Key indicators

Latest: Q3 '26
IndicatorLatestVs year agoLast 8 quarters
Revenue growth2.1%+3.8 pts
Operating margin3.8%-3.9 pts
FCF margin8.7%+4.8 pts
Capex / revenue3.7%+0.0 pts
Diagnosis & Treatment comparable sales growth0%-1 pts
Connected Care comparable sales growth+5%0 pts
Personal Health comparable sales growth+8%-3 pts
Comparable order intake growth+8%0 pts
Image-guided therapy installed systems · 12/31/25≥20,000––

Margins and growth from reported quarters; company KPIs as reported in results releases.

About PHIA

Philips sells diagnostic and interventional equipment, connected monitoring and clinical software, and consumer health devices. Hospital workflow integration and service coverage support repeat business; Enterprise Informatics sits in Connected Care.

Revenue mix
Diagnosis & Treatment 49.7%Connected Care 28.4%Personal Health 21.9%
  • Data Workflow Lockin

    Hospitals integrate imaging and interventional equipment with clinical data and procedural workflows.

  • Service Field Network

    Large installed base supports service contract attachment, uptime guarantees, and upgrade pathways that raise customer switching friction.

  • Data Workflow Lockin

    Monitoring + enterprise informatics software embed into clinical workflows (alarms, dashboards, documentation), making rip-and-replace costly and risky for hospitals.

  • Brand Trust

    Trusted consumer brand supports premium shelf/online placement and repeat purchasing in oral care and grooming categories.

Timeline
  1. Nov 3, 2026

    Respironics reached agreement in principle to resolve DOJ criminal and civil investigations. EUR288m provision recorded, final documentation pending and payment expected Q1 2027. State Attorneys General and other proceedings are excluded. Source: https://www.sec.gov/Archives/edgar/data/313216/000162828026069119/a2026q3-philipsquarterlyen.htm (November 3, 2026).

  2. Sep 30, 2026 · Legal charge −€288M

    Respironics DOJ criminal and civil settlement provision following agreement in principle. Final documentation pending, payment expected Q1 2027; excludes other ongoing proceedings.

  3. Sep 10, 2026

    Philips reported remediation of 99% of actionable sleep-device registrations and 101,000 of 102,000 actionable US ventilator registrations. This reduces recall work, while ventilation remediation and legal investigations remain open.

  4. Sep 1, 2026

    Philips Avent launched its Natural Care Wearable Breast Pump in Western Europe, extending its premium infant-feeding range into a growing wearable category.

  5. Jul 27, 2026

    Philips raised its full-year profit and cash-flow outlook after recognizing a EUR 186 million US tariff refund in Q2. The refund supports cash but does not establish better underlying imaging margins.

Financial record

Fiscal year2016201720182019202020212022202320242025TTMTrendChange 2016–25
Per share (€)
Revenue18.7618.8119.0018.4218.8918.0818.7319.1619.3118.5317.94-0.1%/yr
Cash flow1.261.981.871.952.741.72-0.182.251.681.222.52-0.4%/yr
Earnings0.891.081.371.061.080.64-1.70-0.48-0.900.930.96+0.5%/yr
Free cash flow0.451.070.980.931.760.91-1.031.570.960.521.85+1.8%/yr
Capex0.810.910.881.020.980.800.850.680.720.690.68-1.8%/yr
Dividends0.360.410.420.490.000.510.430.000.000.340.36-0.5%/yr
Book value13.5112.7012.6713.5312.9515.2113.9212.6812.8611.3811.70-1.9%/yr
Diluted shares (M)929945954931917949952948933963990+0.4%/yr
Totals (€B)
Revenue17.417.818.117.117.317.217.818.218.017.817.8+0.3%/yr
Operating income1.51.51.71.41.30.6-1.5-0.10.51.41.6-0.3%/yr
Net income0.81.01.31.01.00.6-1.6-0.5-0.80.91.0+0.9%/yr
Free cash flow0.41.00.90.91.60.9-1.01.50.90.51.8+2.2%/yr
Buybacks0.60.61.01.40.31.60.20.70.40.00.1–
Dividends0.30.40.40.50.00.50.40.00.00.30.4-0.1%/yr
Net cash-2.9-2.5-2.8-2.6-2.5-3.5-5.9-4.7-4.2-4.3-5.4−€1.4B
Margins & returns (%)
Gross margin45.646.047.246.145.241.840.441.043.145.246.4-0.4 pts
Operating margin8.48.59.58.07.33.2-8.6-0.62.98.08.8-0.4 pts
Net margin4.75.77.25.75.73.5-9.1-2.5-4.75.05.4+0.3 pts
FCF margin2.45.75.25.09.35.0-5.58.25.02.810.3+0.4 pts
ROIC8.29.110.07.87.72.7-6.9-0.62.88.18.0-0.1 pts
Return on equity6.68.510.87.88.34.2-12.2-3.8-7.08.28.2+1.6 pts
R&D % of revenue9.69.99.710.410.510.511.710.49.79.59.7-0.0 pts
Stock pay % of revenue–0.70.50.60.60.60.50.50.50.80.9–
Capex % of revenue4.34.84.75.55.24.44.53.53.83.73.8-0.6 pts

Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.

TTM = four quarters to Sep 30, 2026. Per-share values use diluted weighted shares.ROIC = operating income × (1 − 13.0% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases.

Moat

Moat scorecard

Moat score77
Strength
Confidence
Structure
Oligopoly
Durability
durable
Trajectory
stable
Pricing power
moderate
Segments
  • Diagnosis & Treatment49.7%
    2 claims
  • Connected Care28.4%
    1 claim
  • Personal Health21.9%
    2 claims

Moat claims

Applies to
Diagnosis & Treatment
Confidence
Durability
durable
Trajectory
stableas of Jun 30, 2026
Why it holds

Hospitals integrate imaging and interventional equipment with clinical data and procedural workflows. Replacing that equipment requires interface validation and staff training. Enterprise Informatics is reported in Connected Care, so its PACS leadership supports the wider platform rather than a separate Diagnosis & Treatment software business.

Why stable

Long-term imaging partnerships and over 20,000 installed interventional systems support workflow integration. Diagnosis & Treatment comparable sales rose 2% in Q2, but renewal rates are not disclosed.

Indicators
  • Diagnosis & Treatment comparable sales growth0%
  • Comparable order intake growth+8%
  • Image-guided therapy installed systems≥20,000
Risks
  • Cloud-native PACS/VNA reducing vendor lock-in
  • Open standards (DICOM/HL7/FHIR) improving interoperability
  • Hospitals pushing best-of-breed point solutions

Profile change log

  1. Nov 11, 2026 · business change

    Respironics reached agreement in principle to resolve DOJ criminal and civil investigations. EUR288m provision recorded, final documentation pending and payment expected Q1 2027. State Attorneys General and other proceedings are excluded. Source: https://www.sec.gov/Archives/edgar/data/313216/000162828026069119/a2026q3-philipsquarterlyen.htm (November 3, 2026).

  2. Oct 6, 2026 · business change

    Philips reported remediation of 99% of actionable sleep-device registrations and 101,000 of 102,000 actionable US ventilator registrations. This reduces recall work, while ventilation remediation and legal investigations remain open.

  3. Oct 6, 2026 · business change

    Philips Avent launched its Natural Care Wearable Breast Pump in Western Europe, extending its premium infant-feeding range into a growing wearable category.

  4. Oct 6, 2026 · business change

    Philips raised its full-year profit and cash-flow outlook after recognizing a EUR 186 million US tariff refund in Q2. The refund supports cash but does not establish better underlying imaging margins.

  5. Oct 6, 2026 · business change

    Philips issued a Trilogy Evo ventilator correction for delivery and alarm problems. The FDA classified it as the most serious recall type, keeping product reliability central to restoring respiratory-care trust.

  6. Oct 6, 2026 · business change

    Philips bought SpectraWAVE for USD 265 million upfront plus contingent consideration, adding coronary intravascular imaging and AI-based physiology tools to its interventional platform.

  7. Oct 6, 2026 · analyst revision

    Imaging workflow evidence now distinguishes equipment integration from Connected Care Enterprise Informatics. All five existing claims have dated trajectories, counterarguments and tests. Consumer brand demand is widening; equipment workflow and consumable protection remain stable.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreIndustry medianPHIAGEHCMDTRMDORCLPGCL

Hover a point for its values; click a peer to compare. Dashed lines: industry medians.

Global diagnostic imaging and image-guided therapy

As of Oct 9, 2026
OligopolyMedium cyclicality

Global diagnostic imaging, specialized ultrasound and image-guided procedure systems, with related service, software and enterprise imaging workflows. Excludes general patient monitoring, diagnostic agents and standalone therapeutic radiation systems.

  1. GE HealthCare
  2. Siemens Healthineers
  3. Philips
  4. Canon
  5. United Imaging
2025 leaders, no comparable shares · GE HealthCare 2025 Form 10-K
StocksMoatGross m.Op. m.
PHIA7746.4%8.8%
Industry median147552.1%13.3%
Sector median557661.5%17.3%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Ageing populations and chronic disease increase diagnostic scans and minimally invasive procedures.
  • Hospital staff shortages raise demand for faster scans, remote servicing and integrated clinical workflows.
  • AI reconstruction, spectral CT and helium-free MRI can support replacement demand and premium product mix.
  • Hospital financing costs and public budgets control the timing of large equipment orders.
  • Insurance reimbursement for scans and procedures affects equipment utilization and the cash hospitals can reinvest.
Risks
  • Hospital tenders and strong GE HealthCare, Siemens, Canon and local competition constrain prices.
  • China purchasing delays and preference for domestic equipment can weaken multinational demand.
  • Tariffs, currency translation and scarce technical inputs can reduce profit even when comparable demand grows.
  • Patient-safety recalls, cybersecurity failures and strict approval rules can delay launches and damage service trust.
  • Open data standards and independent service firms reduce the value customers place on a single-vendor software or repair system.

Bulls & bears

Key question · as of Nov 11, 2026

Can Philips turn its installed hospital base and consumer demand into lasting profit and cash growth without tariff refunds or renewed recall liabilities?

Arguments

4 forFaded: weakening or settled4 against

What to watch

  1. 1Comparable order intake and conversion into Diagnosis & Treatment sales
  2. 2Segment comparable sales and adjusted EBITA excluding tariff refunds
  3. 3Service attachment, software renewals and replacement-consumable sales when disclosed
  4. 4Respironics remediation, investigation outcomes and recall payments
  5. 5Operating cash flow less gross capex and working-capital outflows

Next check: Read Q4 and FY2026 results when announced, DOJ final settlement documentation and the expected first-quarter 2027 payment; monitor order conversion and consent-decree remediation.

Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 77/100 by <a href="https://www.findmymoat.com/stocks/XAMS:PHIA">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.